Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    ADVL1221
Show Display Options
Rank Status Study
1 Active, not recruiting Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
Conditions: Childhood Alveolar Soft-part Sarcoma;   Childhood Angiosarcoma;   Childhood Epithelioid Sarcoma;   Childhood Fibrosarcoma;   Childhood Gliosarcoma;   Childhood Leiomyosarcoma;   Childhood Liposarcoma;   Childhood Neurofibrosarcoma;   Childhood Synovial Sarcoma;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Osteosarcoma
Interventions: Biological: cixutumumab;   Drug: temsirolimus;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years